Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Whittle

Showing results (71-80 of 74) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 74 results.
Vaccine|March 21, 2026
Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trialAdora Rooyakkers, Lingyun Ye, Pedro E Cahn, et al.
The Biochemical Journal|April 15, 1997
Inhibition of bovine nasal cartilage degradation by selective matrix metalloproteinase inhibitorsK M Bottomley, N Borkakoti, D Bradshaw, et al.
Medrxiv : the Preprint Server for Health Sciences|June 29, 2026
A controlled human infection model for symptomatic pertussis in North America using the pertactin-producing clinical isolate D420May S ElSherif, Kara L Redden, Joanne M Langley, et al.
Annals of Emergency Medicine|December 17, 2023
Clinical Policy: Critical Issues in the Evaluation and Management of Adult Out-of-Hospital or Emergency Department Patients Presenting With Severe Agitation: Approved by the ACEP Board of Directors, October 6, 2023, Molly E W Thiessen, Steven A Godwin, et al.
Pageof 8

Showing results (71-80 of 74) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 74 results.
Vaccine|March 21, 2026
Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trialAdora Rooyakkers, Lingyun Ye, Pedro E Cahn, et al.
The Biochemical Journal|April 15, 1997
Inhibition of bovine nasal cartilage degradation by selective matrix metalloproteinase inhibitorsK M Bottomley, N Borkakoti, D Bradshaw, et al.
Medrxiv : the Preprint Server for Health Sciences|June 29, 2026
A controlled human infection model for symptomatic pertussis in North America using the pertactin-producing clinical isolate D420May S ElSherif, Kara L Redden, Joanne M Langley, et al.
Annals of Emergency Medicine|December 17, 2023
Clinical Policy: Critical Issues in the Evaluation and Management of Adult Out-of-Hospital or Emergency Department Patients Presenting With Severe Agitation: Approved by the ACEP Board of Directors, October 6, 2023, Molly E W Thiessen, Steven A Godwin, et al.
Pageof 8